表紙:精密精神医学の世界市場 - 産業規模、シェア、動向、機会、予測:バイオマーカー別、サンプル別、技術別、用途別、エンドユーザー別、企業別、地域別(2017年~2027年)
市場調査レポート
商品コード
1152254

精密精神医学の世界市場 - 産業規模、シェア、動向、機会、予測:バイオマーカー別、サンプル別、技術別、用途別、エンドユーザー別、企業別、地域別(2017年~2027年)

Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers, By Sample, By Technology, By Application, By End User, By Company and By Region

出版日: | 発行: TechSci Research | ページ情報: 英文 115 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

精密精神医学の世界市場 - 産業規模、シェア、動向、機会、予測:バイオマーカー別、サンプル別、技術別、用途別、エンドユーザー別、企業別、地域別(2017年~2027年)
出版日: 2022年11月01日
発行: TechSci Research
ページ情報: 英文 115 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の精密精神医学の市場規模は、予測期間中の2023年~2027年に目覚ましい成長を遂げると予測されています。

市場成長の主要な要因は、精神疾患発症率の上昇と技術進歩であり、これらが世界の市場成長を後押ししています。市場成長を支えるその他の要因としては、認知度の向上、投資拡大、人口増大、ライフスタイルの変化、シークエンスコストの低下、無機的成長戦略の採用増加、医療インフラに対する政府からの支援などが挙げられます。また、精神疾患発症や兆候に関連するゲノム・プロテオミクス分析を行う研究者による高度な分子診断技術の高い導入率も、市場成長を押し上げると期待される主要な要因です。

当レポートでは、世界の精密精神医学市場について調査分析し、セグメント別・地域別の市場規模・シェア予測、市場力学、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の精密精神医学市場に与える影響

第5章 VOC(顧客の声)

第6章 世界の精密精神医学市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • バイオマーカー別(遺伝子とタンパク質)
    • サンプル別(血液ベースと血液ベース以外)
    • 技術別(シーケンシング、ポリメラーゼ連鎖反応、マイクロアレイ、イムノアッセイ、その他)
    • 用途別(アルツハイマー病、パーキンソン病、自閉症、うつ病、その他)
    • エンドユーザー別(病院・クリニック、学術・調査機関、その他)
    • 企業別(2021年)
    • 地域別
  • 製品市場マップ

第7章 北米の精密精神医学市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • バイオマーカー別
    • サンプル別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 欧州の精密精神医学市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • バイオマーカー別
    • サンプル別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋の精密精神医学市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • バイオマーカー別
    • サンプル別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • アジア太平洋:国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第10章 南米の精密精神医学市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • バイオマーカー別
    • サンプル別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの精密精神医学市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • バイオマーカー別
    • サンプル別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト
    • トルコ

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と開発

第14章 競合情勢

  • Altimate Healthcare
  • PsyProtix, Inc
  • Cerebral-Alto Nanoscience
  • Precision Psychiatric Services, Inc
  • Tempus Labs, Inc.
  • Curis AI Inc.

第15章 戦略的提言

目次
Product Code: 12983

The global precision psychiatry market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include rise in incidences of mental health and technological advancements, which are bolstering the market growth, globally. Precision psychiatry is new field within precision medicine, which seeks to detect and capitalize on individual differences in biology, environment, lifestyle, and social determinants of health to improve mental health prevention, diagnosis, and treatment. The other factors supporting the market's growth are increasing awareness, growing investments, increase in population, changing lifestyle, decreasing cost of sequencing, increasing adoption of inorganic growth strategies and support from governments for healthcare infrastructure. Also, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis associated to the onset and manifestation of psychiatric illnesses are some of the key factors that are projected to bolster the market growth.

Increase in Prevalence of Mental Disorders

Over the past few years, rise in number of people suffering from mild or severe depressive disorders is seen. These mental illness or disorders are basically caused due to chemical, genetic, and anatomical conditions, or psychological origins such as trauma. Thus, to seek better lives for those suffering from mental illness, precision psychiatry is much required, which attributes to the growth of the market, globally. For instance, according to the National Institute of Mental Health, around one in every five U.S. adults suffer from mental illness. Also, in 2020, 25.8% of females were suffering from mental illness.

Increasing Adoption of Inorganic Growth Strategies

Increasing inorganic growth strategies by key players are expected to drive the global precision psychiatry market growth during the forecast period. For instance, in 2021, Alto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021, Atai Life Sciences, a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix, which is a precision psychiatry company.

Increased demand for Genomics as precision psychiatry

From past few years, genomic technologies have advanced the understanding of neuropsychiatric disorders. Genomics plays a significant part in the diagnosis of several genetic disorders. It has ample scope in precision psychiatry as it can advocate medical management constructed on the genetic face of a person with the help of clinical data and AI. It incorporates DNA sequencing methods, recombinant DNA, and bioinformatics for sequencing, assembling, and analyzing the structure and functions of genomes. Many severe mental illnesses, such as schizophrenia and bipolar disorder, are highly inherited, and have a complex pattern of inheritance. These diseases can be identified by using sequencing technology, which evaluates the rare genetic variants. With the use of sequencing technology, psychiatry can ultimately reshape by predicting disease risk and lead to better understanding of aetiology, prognosis, or treatment response. Moreover, the decrease in cost of sequencing is also a key factor to increase the growth of the market.

Market Segmentation

The global precision psychiatry market is segmented into biomarkers, sample, technology, application, end user, and company. Based on biomarker, the market is divided into genetic and protein. Based on sample, the market is divided into blood-based and non-blood-based. Based on non-blood-based, the market is further divided into saliva, urine, cerebral spinal fluid, and others. Based on technology, the market is divided into sequencing, polymerase chain reaction, microarray, immunoassay, and others. Based on application, the market is divided into Alzheimer's disease, Parkinson's disease, autism, depression, and others. Based on end user, the market is divided into hospital & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rise in incidences of mental illness in the country.

Market Players

Altimate Healthcare, PsyProtix, Inc, Cerebral-Alto Nanoscience, Precision Psychiatric Services, Inc, Tempus Labs, Inc., and Curis AI Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global precision psychiatry market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Precision Psychiatry Market, By Biomarker:

  • Genetic
  • Protein

Precision Psychiatry Market, By Sample:

  • Blood Based
  • Non-Blood-Based
    • Saliva
    • Urine
    • Cerebral Spinal Fluid
    • Others
    • Precision Psychiatry Market, By Technology:
  • Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Immunoassay
  • Others

Precision Psychiatry Market, By Application:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Autism
  • Depression
  • Others

Precision Psychiatry Market, By End User:

  • Hospital & Clinics
  • Academic & Research Institutions
  • Others

Precision Psychiatry Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in precision psychiatry market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Precision Psychiatry Market

5. Voice of Customer

6. Global Precision Psychiatry Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Biomarkers (Genetic v/s Protein)
    • 6.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 6.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 6.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 6.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 6.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 6.2.6. By Company (2021)
    • 6.2.7. By Region
  • 6.3. Product Market Map

7. North America Precision Psychiatry Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Biomarkers (Genetic v/s Protein)
    • 7.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 7.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 7.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 7.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 7.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Precision Psychiatry Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Biomarker
        • 7.3.1.2.2. By Sample
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Mexico Precision Psychiatry Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Biomarker
        • 7.3.2.2.2. By Sample
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Canada Precision Psychiatry Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Biomarker
        • 7.3.3.2.2. By Sample
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User

8. Europe Precision Psychiatry Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Biomarkers (Genetic v/s Protein)
    • 8.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 8.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 8.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 8.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 8.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Precision Psychiatry Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Biomarker
        • 8.3.1.2.2. By Sample
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Germany Precision Psychiatry Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Biomarker
        • 8.3.2.2.2. By Sample
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. United Kingdom Precision Psychiatry Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Biomarker
        • 8.3.3.2.2. By Sample
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. Italy Precision Psychiatry Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Biomarker
        • 8.3.4.2.2. By Sample
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Spain Precision Psychiatry Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Biomarker
        • 8.3.5.2.2. By Sample
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Asia-Pacific Precision Psychiatry Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Biomarkers (Genetic v/s Protein)
    • 9.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 9.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 9.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 9.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 9.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Precision Psychiatry Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Biomarker
        • 9.3.1.2.2. By Sample
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. India Precision Psychiatry Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Biomarker
        • 9.3.2.2.2. By Sample
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Korea Precision Psychiatry Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Biomarker
        • 9.3.3.2.2. By Sample
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User
    • 9.3.4. Japan Precision Psychiatry Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Biomarker
        • 9.3.4.2.2. By Sample
        • 9.3.4.2.3. By Technology
        • 9.3.4.2.4. By Application
        • 9.3.4.2.5. By End User
    • 9.3.5. Australia Precision Psychiatry Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Biomarker
        • 9.3.5.2.2. By Sample
        • 9.3.5.2.3. By Technology
        • 9.3.5.2.4. By Application
        • 9.3.5.2.5. By End User

10. South America Precision Psychiatry Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Biomarkers (Genetic v/s Protein)
    • 10.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 10.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 10.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 10.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 10.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Precision Psychiatry Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Biomarker
        • 10.3.1.2.2. By Sample
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Argentina Precision Psychiatry Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Biomarker
        • 10.3.2.2.2. By Sample
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Colombia Precision Psychiatry Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Biomarker
        • 10.3.3.2.2. By Sample
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Middle East and Africa Precision Psychiatry Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Biomarkers (Genetic v/s Protein)
    • 11.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 11.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 11.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 11.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 11.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Precision Psychiatry Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Biomarker
        • 11.3.1.2.2. By Sample
        • 11.3.1.2.3. By Technology
        • 11.3.1.2.4. By Application
        • 11.3.1.2.5. By End User
    • 11.3.2. Saudi Arabia Precision Psychiatry Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Biomarker
        • 11.3.2.2.2. By Sample
        • 11.3.2.2.3. By Technology
        • 11.3.2.2.4. By Application
        • 11.3.2.2.5. By End User
    • 11.3.3. UAE Precision Psychiatry Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Biomarker
        • 11.3.3.2.2. By Sample
        • 11.3.3.2.3. By Technology
        • 11.3.3.2.4. By Application
        • 11.3.3.2.5. By End User
    • 11.3.4. Egypt Precision Psychiatry Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Biomarker
        • 11.3.4.2.2. By Sample
        • 11.3.4.2.3. By Technology
        • 11.3.4.2.4. By Application
        • 11.3.4.2.5. By End User
    • 11.3.5. Turkey Precision Psychiatry Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Biomarker
        • 11.3.5.2.2. By Sample
        • 11.3.5.2.3. By Technology
        • 11.3.5.2.4. By Application
        • 11.3.5.2.5. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Altimate Healthcare
  • 14.2. PsyProtix, Inc
  • 14.3. Cerebral-Alto Nanoscience
  • 14.4. Precision Psychiatric Services, Inc
  • 14.5. Tempus Labs, Inc.
  • 14.6. Curis AI Inc.

15. Strategic Recommendations